

APPENDIX -III

CASH & BANK BALANCE, DEBTORS, OTHER RECEIVABLES, INVENTORIES, TOTAL CURRENT ASSETS,
 SHORT TERM BANK BORROWINGS, CREDITORS, MIS. CURRENT LIABILITIES, PROVISION FOR TAX, PROVISION FOR DIVIDEND,
 OTHER PROVISION, TOTAL CURRENT LIABILITIES, NET WORKING CAPITAL, CREDIT PURCHASE, OPERATIONAL REQUIREMENT FOR CASH IN THE MULTINATIONAL
 DRUGS & PHARMACEUTICAL COMPANIES FOR THE PERIOD 1990-91 TO 1999-00.

NO.	COMPANIES / YEARS	1990-91	1991-92	1992-93	1993-94	1994-95	1995-96	1996-97	1997-98	1998-99	1999-00
CASH AND BANK BALANCE											
1	Abbott laboratories	0.75	0.46	0.63	0.32	1.91	0.61	0.47	0.61	0.31	1.37
2	Aventis pharma	3.71	5.55	11.04	9.68	8.26	6.79	4.12	2.03	0.9	2.43
3	Burrough Wellcome	1.7	6.4	7.14	10.89	13.13	7.44	32.6	43.87	73.34	73.38
4	Duphar-interfran ltd	0.98	1.22	1.22	0.72	1.63	0.85	1.65	2.09	8.93	10.57
5	E Merck India ltd	0.63	1.14	1.06	0.88	0.71	0.89	1.38	3.87	2.18	2.01
6	German Remedies ltd	2.08	1.27	2.04	1.95	6.97	4.14	4.34	5.03	2.68	15.04
7	Glaxo India ltd	12.04	7.83	3.12	43.92	39.78	177.24	65.32	47.16	66.59	46.88
8	Knoll Pharma ltd	0.66	0.6	1.06	26.12	7.7	1.05	2	30.17	78.17	141.09
9	Novartis India ltd	2.24	9.31	7.91	9.91	49.63	44.36	7.54	15.42	16.34	28.2
10	Parke-Davis India ltd	0.8	1.89	1.85	1.69	0.63	0.65	2.74	1.3	1.51	2.72
11	Pfizer ltd	0.3	0.32	0.69	2.24	2.17	1.01	0.68	2.56	8.4	23.28
	TOTAL	25.89	35.99	37.76	108.32	132.52	245.03	122.84	154.11	259.35	346.97
DEBTORS											
1	Abbott laboratories	3.51	4	4.4	4.68	5.95	7.91	8.04	8.91	12.26	14.21
2	Aventis pharma	16.79	19.4	22.5	25.02	14.8	27.31	39.85	69.49	58.49	36.83
3	Burrough Wellcome	4.67	6.16	12.35	22.75	31.97	9.89	8.67	12.41	16.83	22.59
4	Duphar-interfran ltd	7.2	7.11	9.59	13.06	8.86	9.87	4.63	4.54	5.71	5.99
5	E Merck India ltd	19.18	25.11	27.56	18.31	19.3	23.68	24.61	26.83	29.9	31.76
6	German Remedies ltd	6.96	9.35	13.37	14.62	15.56	16.27	21.12	25.22	27.22	31.36
7	Glaxo India ltd	13.52	12.9	17.37	24.67	20.45	37.53	60.79	61.38	74.49	99.29
8	Knoll Pharma ltd	5.69	7.42	8.46	9.32	13.6	21.27	22.94	20.73	19.87	19.36
9	Novartis India ltd	34.76	37.76	50.37	51.35	67.47	102.69	95.4	122.49	113.52	132.28
10	Parke-Davis India ltd	6.78	7.48	9.51	16.06	17.31	16.78	16.75	21.38	14.98	15.45
11	Pfizer ltd	11.43	10.84	15.72	16.61	16.99	19.99	21.55	24.62	23.17	38.1
	TOTAL	130.49	147.53	191.2	216.45	232.26	293.19	324.35	398	396.44	447.22

APPENDIX -III (Contd.)

APPENDIX -III (Contd.)

NO	COMPANIES / YEARS	(Rs. In Crores)										
		1990-91	1991-92	1992-93	1993-94	1994-95	1995-96	1996-97	1997-98	1998-99	1999-00	
OTHER RECEIVABLES												
1	Abbott laboratories	2 39	3 24	4 12	3 64	3 34	3 63	3 71	4 9	5 07	5 09	
2	Aventis pharma	31 38	17 22	16	17 86	27 78	24 54	31 16	49 42	37 3	33 55	
3	Burrough Wellcome	7 91	8 07	11 36	19 51	22 7	21 48	23 77	25 81	25 05	32 47	
4	Duphar-interfran ltd	1 6	1 78	2 73	2 29	2 68	16 01	33 01	29 83	28 67	12 87	
5	E Merck India ltd	5 79	7 34	6 91	5 42	6 87	8 38	7 81	6 77	11 59	11 7	
6	German Remedies ltd	6 77	8 52	8 95	10 79	17 31	22 16	8 03	11 87	9 71	13 06	
7	Glaxo India ltd	30 52	30 01	33 53	39 22	35 3	47 46	57 67	55 52	55 25	66 63	
8	Knoll Pharma ltd	6 35	5 92	7 91	9 91	11 32	9 48	20 71	56 19	33 68	10 63	
9	Novartis India ltd	13 78	22 29	23 41	28 62	50 75	63 01	69 95	76 89	72 99	88 7	
10	Parke-Davis India ltd	6 88	7 39	6 43	5 29	12 69	12 87	20 6	19 05	14 77	14 56	
11	Pfizer ltd	12 46	15 22	11 89	18 23	27 89	24 36	32 34	45 72	39 23	38 39	
	TOTAL	125.83	127	133.24	160.78	218.63	253.38	308.76	381.97	333.31	327.65	
INVENTORIES												
1	Abbott laboratories	8 22	9 13	10 47	8 17	9 58	11 46	12 18	11 17	10 91	16 4	
2	Aventis pharma	58 27	44 31	48 59	70 25	67 41	74 31	69 45	132 31	76 76	93 01	
3	Burrough Wellcome	23 02	27 79	28 39	20 78	28 74	30 55	24 91	31 89	26 75	25 4	
4	Duphar-interfran ltd	11 49	14 11	14 98	18 52	19 92	17 73	14 84	12 77	12 6	10 15	
5	E Merck India ltd	23 41	24 2	30 82	24 07	41 36	42 46	48 6	51 21	53 04	57 25	
6	German Remedies ltd	19 95	23 94	18 11	23 03	23 57	27 63	26 18	28 57	36 83	38 72	
7	Glaxo India ltd	83 39	101 19	118 34	96 06	74 74	96 4	114 95	133 4	127 13	133 26	
8	Knoll Pharma ltd	18 72	25 47	24 14	26 64	36 4	38 7	36 51	31 98	46 33	45 23	
9	Novartis India ltd	55 18	77 71	67 59	74 05	80 82	105 52	142 96	123 56	143 2	140 15	
10	Parke-Davis India ltd	18 73	16 25	24 11	18 22	26 93	19 91	24 84	24 93	24 95	26 98	
11	Pfizer ltd	29 97	30 05	39 4	44 62	44 39	38 74	35 97	32 85	40 18	44 86	
	TOTAL	350.35	394.15	424.94	424.41	453.86	503.41	551.39	614.64	598.68	631.41	

APPENDIX -III (Contd.)

NO	COMPANIES / YEARS	1990-91	1991-92	1992-93	1993-94	1994-95	1995-96	1996-97	1997-98	1998-99	1999-00
TOTAL CURRENT ASSETS											
1	Abbott laboratories	14 87	16 83	19 62	16 81	20 78	23 61	24 4	25 59	28 55	37 07
2	Aventis pharma	110 15	86 48	98 13	122 81	118 25	132 95	144 58	253 25	173 45	165 82
3	Burrough Wellcome	37 3	48 42	59 24	73 93	96 54	69 36	89 95	113 98	141 97	153 84
4	Duphar-interfran ltd	21 27	24 22	28 52	34 59	33 09	44 46	54 13	49 23	55 91	39 58
5	E Merck India ltd	49 01	57 79	66 35	48 68	68 24	75 41	82 4	88 68	96 71	102 72
6	German Remedies ltd	35 76	43 08	42 47	50 39	63 41	70 2	59 67	70 69	76 44	98 18
7	Glaxo India ltd	139 47	151 93	172 36	203 87	170 27	358 63	298 73	297 46	323 46	346 06
8	Knoll Pharma ltd	31 42	39 41	41 57	71 99	69 02	70 5	82 16	139 07	178 05	216 31
9	Novartis India ltd	105 96	147 07	149 28	163 93	248 67	315 58	315 85	338 36	346 05	389 33
10	Parke-Davis India ltd	33 19	33 01	41 9	41 26	57 56	50 21	64 93	66 66	56 21	59 71
11	Pfizer ltd	54 16	56 43	67 7	81 7	91 44	84 1	90 54	105 75	110 98	144 63
	TOTAL	632.56	704.67	787.14	909.96	1037.27	1295.01	1307.34	1548.72	1587.78	1753.25
SHORT TERM BANK BORROWINGS											
1	Abbott laboratories	0 26	5 3	4 62	0 1	0	5 15	8 96	8 23	8 17	3 71
2	Aventis pharma	35 18	19 74	29 59	19 38	9 39	33 23	40 47	65 15	22 79	29 36
3	Burrough Wellcome	8 78	11 36	14 72	6 2	33 88	21 66	4 74	0 65	0	2 82
4	Duphar-interfran ltd	5 7	5 93	7 72	8 84	6 16	2 43	3 29	0	0	0
5	E Merck India ltd	8 83	13 97	15 46	0 76	8 16	21 83	11 77	5 42	0 93	2 35
6	German Remedies ltd	8 81	14 43	13 22	4 99	0 66	3 12	1 51	0	4 66	0
7	Glaxo India ltd	24 05	36 61	29 89	2 53	5 46	19 36	5 3	0	0 84	0
8	Knoll Pharma ltd	9 56	6 05	4 6	12 14	14 45	12 5	0 85	0	0	0
9	Novartis India ltd	24 94	12 5	15	29	36 56	52 45	47 92	21 15	23 07	12 34
10	Parke-Davis India ltd	2 61	2 25	4 66	1 51	12 16	4 88	9 09	33 35	10 99	9 49
11	Pfizer ltd	13 02	18 79	24 05	22 4	23 91	18 3	2 63	0 82	1 56	0
	TOTAL	141.74	146.93	163.53	107.85	150.79	194.91	136.53	134.77	73.01	60.07

APPENDIX -III (Contd.)

APPENDIX -III (Contd.)											
		(Rs. In Crores)									
NNO	COMPANIES / YEARS	1990-91	1991-92	1992-93	1993-94	1994-95	1995-96	1996-97	1997-98	1998-99	1999-00
CREDITORS											
1	Abbott laboratories	2 62	3 93	5 58	3 01	4 26	4 32	8 78	8 84	9 62	9 25
2	Aventis pharma	39 94	28 73	26 48	37 28	36 93	48 67	56 57	101 33	53 16	42 16
3	Burrough Wellcome	9 77	12 83	16 85	16 82	16 91	14 05	21 15	24 76	29 73	26 81
4	Duphar-interfran ltd	10	11 44	11 45	15	14 35	16 35	6 91	7 87	8 78	7 78
5	E Merck India ltd	24 83	31 09	23 19	17 29	23 33	22 8	30 36	27 35	31 94	25 47
6	German Remedies ltd	10 73	12 2	7 97	7 47	11 2	8 99	12 79	15 1	10 5	11 29
7	Glaxo India ltd	55 73	59 08	67 1	61 59	55 09	59 33	100 13	90 88	98 95	93 66
8	Knoll Pharma ltd	11 83	12 03	13 44	17 45	34 05	47 07	57 9	61 47	75 35	59 32
9	Novartis India ltd	25 65	36 48	34 52	37 9	35 7	47 17	71 31	109 47	95 51	111 58
10	Parke-Davis India ltd	12 55	11 09	16 12	13 91	15 44	13 8	26 24	25 07	13 93	19 52
11	Pfizer ltd	13 25	10 11	14 86	22 48	20 8	27 59	26 5	25 27	41 4	39 43
	TOTAL	216.9	229.01	237.56	250.2	268.06	310.14	418.64	497.41	468.87	446.27
MISCELLINEOUS CURRENT LIABILITIES											
1	Abbott laboratories	1 8	2 29	2 58	3 37	4 62	6 13	6 55	5 63	4 4	4 72
2	Aventis pharma	11 1	10 78	10 25	18 46	14 74	15 41	18 1	31 4	54 75	66 68
3	Burrough Wellcome	0 64	1 17	1 41	1 21	0 93	1 35	3 88	4 02	4 02	4 21
4	Duphar-interfran ltd	0 35	0 35	0 43	0 3	0 27	0 27	0 4	0 01	0 29	0 58
5	E Merck India ltd	0 62	1 1	8 37	1 28	1 12	1	1 08	1 47	0 85	9 92
6	German Remedies ltd	0 43	1 02	3 35	4 89	5 08	4 61	12 88	34 26	30 67	31 66
7	Glaxo India ltd	8 02	5 59	6 44	6 27	6 25	6 5	7 9	8 74	8 8	9 08
8	Knoll Pharma ltd	0 06	0 11	0 38	0 56	1 13	0 83	0 24	0 24	0 28	0 35
9	Novartis India ltd	3 86	5 57	35 87	33 36	38	30 46	35 82	29 91	30 11	32 66
10	Parke-Davis India ltd	0 45	0 47	0 63	0 54	0 71	0 74	4 56	6 17	6 9	16 8
11	Pfizer ltd	0 84	0 8	0 76	0 63	1 05	1 79	8 34	12 9	12 36	14 96
	TOTAL	28.17	29.25	70.47	70.87	73.9	69.09	99.75	134.75	153.43	191.62

APPENDIX -III (Contd.)

NO	COMPANIES / YEARS	1990-91	1991-92	1992-93	1993-94	1994-95	1995-96	1996-97	1997-98	1998-99	1999-00
PROVISION FOR TAX											
1	Abbott laboratories	0	0	0	0	0.72	0.77	0.79	0	0	0.04
2	Aventis pharma	0	0	0	0	1.91	0.56	3.67	3.68	3.86	5.76
3	Burrough Wellcome	0	0.99	0	0	0.26	0.19	0	0	1.1	1.62
4	Duphar-interfran ltd	0.1	0.23	0.31	0.27	0.21	0.21	0	0	0	0
5	E Merck India ltd	0	0	0	0	0	0.92	0	0.55	1.53	1.96
6	German Remedies ltd	3.19	3.19	3.21	7.06	12.18	17.03	0	0	0	0
7	Glaxo India ltd	3.14	4.37	3.06	3.99	4.25	4.45	3.7	5.69	5.76	8.55
8	Knoll Pharma ltd	2.15	3.79	3.74	4.77	2.18	2.3	4.94	17.51	14.74	9.4
9	Novartis India ltd	0.41	0	0	0	0	6.83	21.59	33.72	10.5	9.68
10	Parke-Davis India ltd	0	0.21	0.03	0.6	0.17	0	0.13	0.16	0.19	0.07
11	Pfizer ltd	1.34	1.21	0.2	0	0	2.46	5.74	6.61	2.61	9.24
	TOTAL	10.33	13.99	10.55	19.58	21.43	37.53	40.33	70.18	43.18	41.6
PROVISION FOR DIVIDEND											
1	Abbott laboratories	0	0	0	0.27	0.34	0.34	0	0	0	0.28
2	Aventis pharma	1.92	1.92	1.92	2.47	6.91	8.06	9.21	4.61	10.36	2.3
3	Burrough Wellcome	0.99	0	1.08	1.47	1.87	0.56	3.44	3.67	4.59	5.51
4	Duphar-interfran ltd	0.28	0.32	0.32	0.32	0.32	0.48	0.63	0.63	1.26	1.26
5	E Merck India ltd	1.19	0.61	0.44	2.36	3.37	3.71	4.55	5.39	6.24	7.08
6	German Remedies ltd	0.72	0.59	0.33	1.14	1.65	2.06	2.47	3.71	5.77	7.42
7	Glaxo India ltd	3	3.6	5.4	10.76	52.33	104.61	23.91	23.91	29.89	35.87
8	Knoll Pharma ltd	2.59	2.75	2.92	3.08	3.4	2.84	5.27	6.48	10.53	65.61
9	Novartis India ltd	3.72	3.45	3.45	3.98	5.31	5.84	10.2	12.74	27.08	47.79
10	Parke-Davis India ltd	2.89	2.89	3.62	4.22	4.82	5.42	6.03	6.03	6.03	0
11	Pfizer ltd	2.34	1.17	2.34	3.52	1.76	2.34	4.69	3.52	4.69	5.86
	TOTAL	19.64	17.3	22.09	33.66	82.08	135.92	70.4	70.69	106.72	179.19

APPENDIX -III (Contd.)

NO.	COMPANIES / YEARS	1990-91	1991-92	1992-93	1993-94	1994-95	1995-96	1996-97	1997-98	1998-99	1999-00
OTHER PROVISIONS											
1	Abbott laboratories	0	0	0	0	0	0	0	0.24	0.36	0.43
2	Aventis pharma	0	0	0	0	0	0	0	0.92	0.46	1.14
3	Burrough Wellcome	0.6	0.34	0.11	0	0.61	0.43	0.38	0.9	0.95	1.13
4	Duphar-interfran ltd	0	0	0	0	0	0	0	0	0.08	0.18
5	E Merck India ltd	0	0.31	0.38	0.35	0.44	0.53	1.29	3.29	6.18	7.26
6	German Remedies ltd	0	0	0	0	0	0	0.25	0.37	1.88	2.36
7	Glaxo India ltd	0.1	1.1	0.1	0.06	0.06	0.06	2.1	4.6	6.97	10.64
8	Knoll Pharma ltd	0	0	0	0	0	0	0	0.65	1.05	7.22
9	Novartis India ltd	0	0.95	0.7	0.19	0.13	2.87	4.97	6.42	8.02	10.16
10	Parke-Davis India ltd	0.51	0.51	0.51	0.51	0.51	1.36	1.97	1.31	1.78	1.95
11	Pfizer ltd	0.86	0.45	0.48	0.43	0.54	4.45	5.31	10.5	13.17	8.66
TOTAL		2.07	3.66	2.28	1.54	2.29	9.7	17.43	28.94	41.75	51.06
TOTAL CURRENT LIABILITIES											
1	Abbott laboratories	4.68	11.52	13.05	7.54	9.99	16.39	24.53	23.06	22.94	18.93
2	Aventis pharma	88.14	61.17	68.24	79.5	68.53	109.04	128.95	206.81	147.96	144.53
3	Burrough Wellcome	20.78	26.69	34.17	25.96	54.39	38.05	33.59	35.1	40.91	40.65
4	Duphar-interfran ltd	16.43	18.27	20.23	24.73	21.31	19.53	11.23	8.59	10.51	10.13
5	E Merck India ltd	35.47	47.08	47.84	22.04	37.34	49.87	49.6	44.45	48.1	52.95
6	German Remedies ltd	23.88	31.43	28.08	25.55	30.77	35.81	29.9	53.44	53.48	52.73
7	Glaxo India ltd	94.04	110.35	111.99	85.2	123.44	194.31	143.04	133.82	151.21	157.8
8	Knoll Pharma ltd	26.19	24.73	25.08	38	55.21	65.54	69.2	86.35	101.95	141.9
9	Novartis India ltd	58.58	58.95	89.54	104.43	115.7	145.62	191.81	213.41	194.29	224.21
10	Parke-Davis India ltd	19.01	17.42	25.57	21.29	33.81	26.2	48.02	72.09	39.82	47.83
11	Pfizer ltd	31.65	32.53	42.69	49.46	48.06	56.93	53.21	59.62	75.79	78.15
TOTAL		418.85	440.14	506.48	483.7	598.55	757.29	783.08	936.74	886.96	969.81

APPENDIX -III (Contd.)												(Rs. In Crores)	
NO	COMPANIES / YEARS	1990-91	1991-92	1992-93	1993-94	1994-95	1995-96	1996-97	1997-98	1998-99	1999-00		
NET WORKING CAPITAL													
1	Abbott laboratories	10 19	5 31	6 57	9 27	10 79	7 22	-0 13	2 53	5 61	18 14		
2	Aventis pharma	22 01	25 31	29 89	43 31	49 72	23 91	15 63	46 44	25 49	21 29		
3	Burrough Wellcome	16 52	21 73	25 07	47 97	42 15	31 31	56 36	78 88	101 06	113 19		
4	Duphar-interfran ltd	4 84	5 95	8 29	9 86	11 78	24 93	42 9	40 64	45 4	29 45		
5	E Merck India ltd	13 54	10 71	18 51	26 64	30 9	25 54	32 8	44 23	48 61	49 77		
6	German Remedies ltd	11 88	11 65	14 39	24 84	32 64	34 39	29 77	17 25	22 96	45 45		
7	Glaxo India ltd	45 43	41 58	60 37	118 67	46 83	164 32	155 69	163 64	172 25	188 26		
8	Knoll Pharma ltd	5 23	14 68	16 49	33 99	13 81	4 96	12 96	52 72	76 1	74 41		
9	Novartis India ltd	47 38	88 12	59 74	59 5	132 97	169 96	124 04	124 95	151 76	165 12		
10	Parke-Davis India ltd	14 18	15 59	16 33	19 97	23 75	24 01	16 91	-5 43	16 39	11 88		
11	Pfizer ltd	22 51	23 9	25 01	32 24	43 38	27 17	37 33	46 13	35 19	66 48		
	TOTAL	213.71	264.53	280.66	426.26	438.72	537.72	524.26	611.98	700.82	783.44		
CREDIT PURCHASE													
1	Abbott laboratories	14 65	17 68	28 31	23 33	21 77	21 88	23 08	25 66	27 28	23 67		
2	Aventis pharma	125 69	113 42	130 15	177 95	117 67	140 61	167 47	226 05	184 23	193 83		
3	Burrough Wellcome	40 99	57 82	61 71	72 3	76 63	48 23	67 83	75 04	68 27	66 5		
4	Duphar-interfran ltd	17 94	24 69	24 45	29 63	25 95	28 25	15 13	14 43	16 58	14 23		
5	E Merck India ltd	48 37	54 76	68 14	55 98	75 29	72 16	89 18	86 64	86 66	87 29		
6	German Remedies ltd	31 61	38 39	40 02	45 03	46 82	54 97	56 89	62 29	76 22	74 46		
7	Glaxo India ltd	152 19	191 61	239 62	250 29	205 71	142 41	210 21	228 97	243 46	269 96		
8	Knoll Pharma ltd	30 63	42 96	52 57	53 91	46 95	38 05	48 28	48 02	43 75	48 67		
9	Novartis India ltd	85 81	102 72	89 6	93 2	96 03	96 01	169 13	165 24	188 24	185 2		
10	Parke-Davis India ltd	23 9	22 32	25 93	23 06	31 48	25 37	40	27 7	17 45	20 72		
11	Pfizer ltd	40 62	49 87	66 74	83 18	78 71	72 71	78 82	34 52	60 7	69 66		
	TOTAL	612.4	716.24	827.24	907.86	823.01	740.65	966.02	994.56	1012.84	1054.19		

APPENDIX -III (Contd.)		(Rs. In Crores)									
NO	COMPANIES / YEARS	1990-91	1991-92	1992-93	1993-94	1994-95	1995-96	1996-97	1997-98	1998-99	1999-00
OPERATIONAL REQUIREMENT.											
1	Abbott laboratories	25 20	30 15	43 97	40 15	40 87	43 89	39 96	46 31	65 78	71 28
2	Aventis pharma	200 87	190 42	217 54	300 28	239 36	271 45	312 84	428 43	353 44	374 81
3	Burrough Wellcome	73 15	95 82	104 72	121 05	131 84	89 05	138 16	138 72	134 22	131 57
4	Duphar-interfran ltd	31 22	39 83	42 52	50 49	48 29	59 15	33 83	35 21	41 10	39 16
5	E Merck India ltd	72 64	82 66	99 09	89 12	117 10	116 13	140 57	149 65	153 16	169 03
6	German Remedies ltd	56 50	67 47	73 64	82 55	89 00	101 65	109 17	120 78	145 75	158 75
7	Glaxo India ltd	311.36	382 00	428 60	468 26	440 70	327.56	463 41	529 26	555 06	553 64
8	Knoll Pharma ltd	75 42	96 84	117 02	127 93	139 19	110 47	129 89	138 16	136 59	154 88
9	Novartis India ltd	156 99	184 27	175 45	176 08	179 80	192 34	352 12	352 07	379 59	388 69
10	Parke-Davis India ltd	85 87	94 68	106 39	108 70	128.14	125 08	124 49	123 27	111 24	130 17
11	Pfizer ltd	92 51	108 27	143 31	176.75	189 79	196 60	205 25	113 55	200 16	224 43
	TOTAL	1181.73	1372.41	1552.25	1741.36	1744.08	1633.37	2049.69	2175.41	2276.09	2396.41

SOURCE: ANNUAL REPORTS OF SELECTED MULTINATIONAL DRUGS AND PHARMACEUTICAL COMPANIES DURING THE PERIOD 1990-91 TO 1999-00